Merck’s President of Global Human Health Adam H. Schechter to Leave Merck Frank Clyburn Named Chief Commercial Officer & Mi...
December 10 2018 - 4:30PM
Business Wire
Merck (NYSE: MRK), known as MSD outside the United States and
Canada, today announced that Adam H. Schechter, president of Global
Human Health (GHH), is stepping down from his current position as
of Dec. 31, 2018, and will be shifting to an advisory capacity to
the CEO. The company is taking the opportunity to reshape its
commercial organization and is creating two new Executive Committee
roles. Frank Clyburn has been promoted to Chief Commercial Officer
and Michael Nally has been promoted to Chief Marketing Officer.
Schechter has been the president of GHH since 2010. He joined
the company in 1988. Schechter has been responsible for the
performance of our human health business during a period of
significant change, and also evolved Merck’s commercial
organization to strengthen the company’s ability to bring its
medicines and vaccines to people in more than 140 countries around
the world. In addition to his accomplishments in Merck’s commercial
organization throughout his 30-year career, Schechter led the
integration of Merck and Schering-Plough, a significant milestone
in the creation of today’s Merck.
“Adam’s leadership and unwavering dedication to finding new ways
to bring Merck’s medicines and vaccines to more patients around the
world have been hallmarks of his time at Merck. I have relied on
his experience and expertise as we evolved a world-class commercial
organization, spanning primary care, hospital and specialty,
vaccines and oncology,” said Kenneth C. Frazier, Chairman and Chief
Executive Officer, Merck. “Because of him we are better positioned
to address future opportunities and challenges as a global
biopharmaceutical company, and Frank and Mike have a great
foundation upon which to build future success.”
“It has been my honor to be a part of Merck for 30 years and to
lead Global Human Health since 2010,” Schechter said. “I am proud
of how we have transformed our business and have been able to
ensure that Merck’s remarkable medicines and vaccines are available
to so many people around the world. I know that Frank and Mike
share that passion for achieving Merck’s mission, and I am
confident that they will build on GHH’s track record of driving
growth and continue the momentum we have across our global business
today.”
Frank Clyburn, who will take on the role of Chief Commercial
Officer, effective Jan. 1, 2019, has held a number of leadership
positions across Merck. Most recently, Clyburn was the President of
the Global Oncology business. In his new role, Clyburn will report
directly to Ken Frazier and will be a member of the Executive
Committee. He will be responsible for all operations and P&L
across Merck’s human health commercial portfolio globally. Clyburn
joined Merck in 2008 and has had responsibility for numerous global
pharmaceutical franchises, including diabetes, cardiovascular and
women’s health, as well as leadership of marketing and sales
teams.
Michael Nally, who will become Chief Marketing Officer,
effective Jan. 1, 2019, most recently led the company’s Vaccines
business. In his new role, Nally will report directly to Ken
Frazier and will be a member of the Executive Committee. Nally will
be responsible for Global Marketing and long-term franchise
strategy across the portfolio. Nally has been at Merck since 2003
and served in a number of roles with responsibilities including
being the Managing Director of UK, Ireland and Sweden as well a
variety of roles in Commercial Operations, Business Development and
Investor Relations.
About Merck
For more than a century, Merck, a leading global
biopharmaceutical company known as MSD outside of the United States
and Canada, has been inventing for life, bringing forward medicines
and vaccines for many of the world's most challenging diseases.
Through our prescription medicines, vaccines, biologic therapies
and animal health products, we work with customers and operate in
more than 140 countries to deliver innovative health solutions. We
also demonstrate our commitment to increasing access to health care
through far-reaching policies, programs and partnerships. Today,
Merck continues to be at the forefront of research to advance the
prevention and treatment of diseases that threaten people and
communities around the world - including cancer, cardio-metabolic
diseases, emerging animal diseases, Alzheimer's disease and
infectious diseases including HIV and Ebola. For more information,
visit www.merck.com and connect with us on Twitter,
Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc.,
Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J.,
USA (the “company”) includes “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These statements are
based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties.
If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of pharmaceutical industry regulation and health care
legislation in the United States and internationally; global trends
toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory
approval; the company’s ability to accurately predict future market
conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk;
dependence on the effectiveness of the company’s patents and other
protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s 2017
Annual Report on Form 10-K and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181210005816/en/
Media Contacts:Pam Eisele, (267) 305-3558Jennifer Mauer, (908)
740-1808Investor Contacts:Peter Dannenbaum, (908) 740-1037Teri
Loxam, (908) 740-1986
Merck (NYSE:MRK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Sep 2023 to Sep 2024